Phillip J. Koo, MD, presented “Role of Molecular Targeted Imaging in Oligometastatic Disease” during the 34th International Prostate Cancer Update on February 12, 2024, in Vail, Colorado.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Koo, Phillip J. “Role of Molecular Targeted Imaging in Oligometastatic Disease.” February 2024. Accessed Nov 2024. https://grandroundsinurology.com/role-of-molecular-targeted-imaging-in-oligometastatic-disease/
Role of Molecular Targeted Imaging in Oligometastatic Disease – Summary
Phillip J. Koo, MD, explores the current state and evolution of the role of molecular targeted imaging in oligometastatic prostate cancer. He begins by examining oligometastatic disease as a diagnosis and highlights the importance of shared decision-making in approaching treatment and management.
Dr. Koo then reviews recent trials examining the impact of various treatments on oligometastatic disease, including the EMBARK, STOMP, and ORIOLE trials. He discusses weaknesses in these trials, with particular emphasis on the lack of risk stratification in each trial and the lack of PSMA-PET in the EMBARK and STOMP trials.
On the topic of progression, Dr. Koo highlights current weaknesses in detecting microscopic disease, which allows micrometastatic disease to progress until it becomes oligometastatic. He discusses the weaknesses of BCR and the low sensitivity of initial diagnostic imaging.
Dr. Koo concludes by outlining future directions for research. He emphasizes the importance of keeping patient goals top-of-mind when exploring treatments.
About The 34th Annual International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. The 34th iteration of the meeting occurred February 11-14, 2024 in Vail, Colorado. To view more educational presentations from IPCU 34, visit our collection page.
ABOUT THE AUTHOR
Phillip J. Koo, MD, is the Chief of Diagnostic Imaging at the Banner MD Anderson Cancer Center in Phoenix, Arizona. Prior to this, he was Chief of Nuclear Medicine and Associate Professor of Radiology at the University of Colorado School of Medicine in Aurora, Colorado. He completed his fellowship at the Harvard Medical School Joint Program in Nuclear Medicine in Boston, Massachusetts. Dr. Koo is a diplomate of both the American Board of Radiology (ABR) and American Board of Nuclear Medicine(ABNM).
